Literature DB >> 14663441

Salivary duct carcinoma.

A Sefik Hosal1, Chunyang Fan, Leon Barnes, Eugene N Myers.   

Abstract

Salivary duct carcinoma (SDC) is a highly malignant tumor that is histologically similar to ductal carcinoma of the breast. This article presents the clinicopathologic features of 15 patients with SDC arising in the salivary glands. The majority of patients were male and aged 65 years or older. The tumor was most often located in the parotid gland. Pain, facial palsy, and presence of calcification in the CT scan were diagnostic features suggestive of SDC. Histologically, 27% of the tumors arose from pre-existing pleomorphic adenoma. Perineural and lymphatic invasion were common findings. There was an extensive cervical lymph node involvement (73%). Distant metastasis was the most common cause of failure. Although SDC exhibits an unpredictable clinical course, total parotidectomy with neck dissection and adjunctive radiation therapy appear to be appropriate for local and regional control of this aggressive neoplasm.

Entities:  

Mesh:

Year:  2003        PMID: 14663441     DOI: 10.1016/S0194-59980301386-X

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   5.591


  31 in total

1.  Salivary duct carcinomas: clinical and CT and MR imaging features in 20 patients.

Authors:  Young Cheol Weon; Sun-Won Park; Hyung-Jin Kim; Han-Sin Jeong; Young-Hyeh Ko; In Suh Park; Sung Tae Kim; Chung Hwan Baek; Young-Ik Son
Journal:  Neuroradiology       Date:  2012-02-04       Impact factor: 2.804

2.  [Ductal carcinoma of the parotid gland with the clinical picture of obstructive sialadenitis].

Authors:  F Hengstermann; M Tisch; K Kraft; H Maier
Journal:  HNO       Date:  2005-09       Impact factor: 1.284

3.  Salivary Duct Carcinoma of Parotid Gland: a Rare Tumor.

Authors:  Giridhar Chidananda-Murthy; Jayanthi Chandran
Journal:  Indian J Surg Oncol       Date:  2018-12-12

4.  Metastatic Salivary Ductal Carcinoma to the Mastoid Segment of the Facial Nerve.

Authors:  Joshua E Fabie; Jonathan L Hatch; Ashley W Cross; Samuel L Oyer; David M Neskey; Theodore R McRackan
Journal:  Otol Neurotol       Date:  2018-09       Impact factor: 2.311

5.  Management and outcome of salivary duct carcinoma in major salivary glands.

Authors:  Elina Salovaara; Olli Hakala; Leif Bäck; Petri Koivunen; Kauko Saarilahti; Fabricio Passador-Santos; Ilmo Leivo; Antti A Mäkitie
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-03-22       Impact factor: 2.503

6.  Distant Metastases in Patients with Carcinoma of the Major Salivary Glands.

Authors:  Safina Ali; Robert Bryant; Frank L Palmer; Monica DiLorenzo; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Ann Surg Oncol       Date:  2015-03-06       Impact factor: 5.344

7.  Salivary duct carcinoma: evaluation of treatment and outcome in a tertiary referral institute.

Authors:  Ann-Jean C C Beck; Peter J F M Lohuis; Abrahim Al-Mamgani; Laura A Smit; Willem M C Klop
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-05-21       Impact factor: 2.503

8.  Establishment and genomic characterization of primary salivary duct carcinoma cell line.

Authors:  Jie Li; Yohitsugu Mitani; Pulivarthi H Rao; Laszlo Perlaky; Bin Liu; Randal S Weber; Adel K El-Naggar
Journal:  Oral Oncol       Date:  2017-05-02       Impact factor: 5.337

9.  Survival rates and prognostic factors for infiltrating salivary duct carcinoma: Analysis of 228 cases from the Surveillance, Epidemiology, and End Results database.

Authors:  Vijayvel Jayaprakash; Mihai Merzianu; Graham W Warren; Hassan Arshad; Wesley L Hicks; Nestor R Rigual; Maureen A Sullivan; Mukund Seshadri; James R Marshall; David M Cohan; Yujie Zhao; Anurag K Singh
Journal:  Head Neck       Date:  2013-10-07       Impact factor: 3.147

10.  A 20-Year Review of 75 Cases of Salivary Duct Carcinoma.

Authors:  Mark R Gilbert; Arun Sharma; Nicole C Schmitt; Jonas T Johnson; Robert L Ferris; Umamaheswar Duvvuri; Seungwon Kim
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2016-05-01       Impact factor: 6.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.